Hemophilia
📧 Sign up to get email alerts when something new happens for Hemophilia.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-07-16EMA Authorised: Elocta (efmoroctocog alfa) — Swedish Orphan Biovitrum AB (publ)
Authorisation granted for Elocta (efmoroctocog alfa) by EMA for Hemophilia A, manufacturer Swedish Orphan Biovitrum AB (publ).
-
EMA approval · 2026-07-16EMA Authorised: Hympavzi (marstacimab) — Pfizer Europe MA EEIG
EMA authorised Hympavzi (marstacimab) for hemophilia A and B, expanding treatment options for these conditions.
-
EMA approval · 2026-07-09EMA Authorised: Adynovi (rurioctocog alfa pegol) — Baxalta Innovations GmbH
EMA authorised Adynovi (rurioctocog alfa pegol) for Hemophilia A, issued by Baxalta Innovations GmbH.
-
EMA approval · 2026-07-08EMA Authorised: Altuvoct (Efanesoctocog alfa) — Swedish Orphan Biovitrum AB (publ)
EU authorization of Altuvoct (efanesoctocog alfa) for Hemophilia A.
-
EMA approval · 2026-07-06EMA Authorised: Altuvoct (Efanesoctocog alfa) — Swedish Orphan Biovitrum AB (publ)
EMA has authorised Altuvoct (efanesoctocog alfa) for Hemophilia A, marking an orphan medicine approval by Swedish Orphan Biovitrum AB (publ)…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-04-24EMA Authorised: Advate (octocog alfa) — Takeda Manufacturing Austria AG
The EMA authorised Advate (octocog alfa) by Takeda Manufacturing Austria AG for Hemophilia A, with a decision dated 21 May 2025.
-
EMA approval · 2026-03-19EMA Authorised: Hympavzi (marstacimab) — Pfizer Europe MA EEIG
The EMA authorised Hympavzi (marstacimab) for treatment of hemophilia A and hemophilia B.
-
EMA approval · 2026-03-04EMA Authorised: Hemgenix (Etranacogene dezaparvovec) — CSL Behring GmbH
The EMA authorised Hemgenix (etranacogene dezaparvovec) from CSL Behring for hemophilia B. The approval is conditional and carries orphan me…
-
FDA approval · 2026-02-27FDA Approved: DESMOPRESSIN ACETATE — Original Application (Caplin Steriles Limited)
FDA approved Desmopressin Acetate from Caplin Steriles Limited under an Original Application (ANDA). This marks the approval of a generic De…
-
FDA approval · 2026-02-25FDA Approved: DESMODA — Original Application (Eton Pharmaceuticals, Inc.)
FDA approves DESMODA (desmopressin acetate oral solution) under an original NDA from Eton Pharmaceuticals; the product provides a new oral f…
-
EMA approval · 2026-01-14EMA Authorised: Roctavian (valoctocogene roxaparvovec) — BioMarin International Limited
The European Medicines Agency authorised Roctavian (valoctocogene roxaparvovec) from BioMarin International Limited as a conditional, orphan…
-
EMA approval · 2025-12-19EMA Authorised: Altuvoct (Efanesoctocog alfa) — Swedish Orphan Biovitrum AB (publ)
The EMA authorised Altuvoct (efanesoctocog alfa) for Hemophilia A, with orphan medicine designation.
-
EMA approval · 2025-12-11EMA Authorised: Afstyla (lonoctocog alfa) — CSL Behring GmbH
Afstyla (lonoctocog alfa) by CSL Behring GmbH has been authorised in the EU for the treatment of Hemophilia A.
-
EMA approval · 2025-12-10EMA Authorised: Kovaltry (octocog alfa) — Bayer AG
The EMA authorised Kovaltry (octocog alfa) from Bayer AG for the treatment of Hemophilia A. Decision date: 13 August 2025.
-
EMA approval · 2025-12-05EMA Authorised: Adynovi (rurioctocog alfa pegol) — Baxalta Innovations GmbH
The European Medicines Agency authorized Adynovi (rurioctocog alfa pegol) from Baxalta Innovations GmbH for use in Hemophilia A.
-
EMA approval · 2025-12-04EMA Authorised: Jivi (Damoctocog alfa pegol) — Bayer AG
The European Medicines Agency has authorised Bayer's Jivi (damoctocog alfa pegol) for the treatment of Hemophilia A in the EU.
-
EMA approval · 2025-11-25EMA Authorised: Refixia (nonacog beta pegol) — Novo Nordisk A/S
The European Medicines Agency authorised Refixia, a nonacog beta pegol product from Novo Nordisk A/S, for the treatment of Hemophilia B.
-
EMA approval · 2025-11-21EMA Authorised: Obizur (susoctocog alfa) — Baxalta Innovations GmbH
The European Medicines Agency authorised Obizur (susoctocog alfa) from Baxalta Innovations GmbH for the treatment of Hemophilia A.
-
EMA approval · 2025-09-25EMA Authorised: Alhemo (concizumab) — Novo Nordisk A/S
EMA authorised Alhemo (concizumab) by Novo Nordisk A/S for the treatment of hemophilia A and hemophilia B.
-
EMA approval · 2025-09-10EMA Authorised: Hemlibra (emicizumab) — Roche Registration Limited
The EMA authorised Hemlibra (emicizumab) for Hemophilia A with Roche Registration Limited as the marketing authorization holder, decision da…
-
FDA approval · 2025-08-27FDA Approved: DESMOPRESSIN ACETATE — Supplemental Application (Avenacy, Inc.)
FDA approved a supplemental application for Desmopressin Acetate by Avenacy, Inc.
-
FDA approval · 2025-07-31FDA Approved: ALHEMO — Supplemental Application (Novo Nordisk)
The FDA document relates to a supplemental application for ALHEMO (concizumab) submitted by Novo Nordisk.
-
FDA approval · 2025-07-08FDA Approved: HEMLIBRA — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for Hemlibra (emicizumab) from Genentech, Inc., updating the labeling to reflect the approved supple…
-
FDA approval · 2025-05-02FDA Approved: ALHEMO — Supplemental Application (Novo Nordisk)
FDA approved a supplemental application for ALHEMO (Concizumab) from Novo Nordisk, expanding the product's regulatory status.
-
EMA approval · 2025-05-02EMA Authorised: Alprolix (eftrenonacog alfa) — Swedish Orphan Biovitrum AB (publ)
The EMA authorised Alprolix (eftrenonacog alfa) from Swedish Orphan Biovitrum AB (publ) for Hemophilia B. It is designated as an orphan medi…